Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Bot

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Investigation|July 26, 2022
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responsesGabrielle Romain, Paolo Strati, Ali Rezvan, et al.
Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumorsKent A Smith, Brenna L Meisenburg, Victor L Tam, et al.
Nature Medicine|April 16, 2020
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaJennifer N Brudno, Norris Lam, Danielle Vanasse, et al.
Nature Medicine|January 22, 2020
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaJennifer N Brudno, Norris Lam, Danielle Vanasse, et al.
Stem Cell Research & Therapy|May 1, 2026
CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine modelCéline Marigny, Gaëlle Revet, Anne Berger, et al.
Blood Cancer Discovery|November 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, et al.
Nature Cancer|May 15, 2024
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profilingAli Rezvan, Gabrielle Romain, Mohsen Fathi, et al.
Nature Cancer|May 22, 2024
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profilingAli Rezvan, Gabrielle Romain, Mohsen Fathi, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Investigation|July 26, 2022
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responsesGabrielle Romain, Paolo Strati, Ali Rezvan, et al.
Journal of Translational Medicine|November 7, 2012
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapiesAdrian Bot, Mark Ahn, Marnix Bosch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumorsKent A Smith, Brenna L Meisenburg, Victor L Tam, et al.
Nature Medicine|April 16, 2020
Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaJennifer N Brudno, Norris Lam, Danielle Vanasse, et al.
Nature Medicine|January 22, 2020
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaJennifer N Brudno, Norris Lam, Danielle Vanasse, et al.
Stem Cell Research & Therapy|May 1, 2026
CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine modelCéline Marigny, Gaëlle Revet, Anne Berger, et al.
Blood Cancer Discovery|November 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, et al.
Nature Cancer|May 15, 2024
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profilingAli Rezvan, Gabrielle Romain, Mohsen Fathi, et al.
Nature Cancer|May 22, 2024
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profilingAli Rezvan, Gabrielle Romain, Mohsen Fathi, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
Pageof 12